Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12611220 | 1.00 | DPP4 (0.38) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL10001156 | 1.00 | DPP4 (0.38) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL860138 | 0.94 | NOS2 (0.43) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL800609 | 0.94 | NOS2 (0.43) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL14296385 | 0.94 | NOS2 (0.43) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL10037272 | 0.87 | NOS3 (0.37) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL19844516 | 0.87 | NOS3 (0.37) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL19844511 | 0.87 | NOS3 (0.37) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL27859825 | 0.79 | NOS2 (0.42) | DPP4DPP8DPP9NOS2FAP | |
| SCHEMBL25096659 | 0.78 | DPP4 (0.39) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-9381200-B2 | Nitrogen containing compounds | WOCKHARDT LIMITED (IN) | 2016-07-05 | — | — | US | disclosed |
| US-20150328201-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2015-11-19 | — | — | US | disclosed |
| US-9132133-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-09-15 | — | — | US | disclosed |
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2015-06-25 | — | — | US | disclosed |
| US-8987297-B2 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2015-03-24 | — | — | US | disclosed |
| US-20150005285-A1 | Nitrogen containing compounds | WOCKHARDT LIMITED (IN) | 2015-01-01 | — | — | US | disclosed |
| US-8853197-B1 | Nitrogen containing compounds | WOCKHARDT LTD. (IN) | 2014-10-07 | — | — | US | disclosed |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | WOCKHARDT LIMITED (IN) | 2014-09-18 | — | — | US | disclosed |
| US-8822450-B2 | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LTD. (IN) | 2014-09-02 | — | — | US | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | WOCKHARDT LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-22 | — | — | US | disclosed |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-07-14 | — | — | US | disclosed |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-07-14 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174133-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | DPP4 3717/4885DPP8 3804/4885DPP9 2965/4885 |
| US-11833209-B2 | Formulated and/or co-formulated liposome compositions containing PD-1 antagonist prodrugs useful in the treatment of cancer and methods thereof | CD274, PDCD1LG2, PDCD1 | DPP4 1304/4885DPP8 980/4885DPP9 1049/4885 |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | KIF2C, SKP1, KIF5B | DPP4 4262/4885DPP8 3868/4885DPP9 3865/4885 |
| US-20150005285-A1 | Nitrogen containing compounds | NOS2, NOS1, NCF1 | DPP4 3717/4885DPP8 3804/4885DPP9 2965/4885 |
| US-10253027-B2 | Aryl lactam kinase inhibitors | AAK1, ADCK1, ANKK1 | DPP4 3458/4885DPP8 2120/4885DPP9 1705/4885 |
| US-20140148431-A1 | 1,6- Diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections | ODC1, AOC1, CASP7 | DPP4 633/4885DPP8 501/4885DPP9 283/4885 |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | DPP4 4609/4885DPP8 4330/4885DPP9 4232/4885 |
| US-20150328201-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | DPP4 3717/4885DPP8 3804/4885DPP9 2965/4885 |
| US-20200331925-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION | MKI67, CCNC, CCNI | DPP4 4365/4885DPP8 4519/4885DPP9 4666/4885 |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | DPP4 4652/4885DPP8 4436/4885DPP9 4328/4885 |
| US-20120077711-A1 | Novel Ligands and Libraries of Ligands | LSS, ABCG2, SELL | DPP4 3178/4885DPP8 2940/4885DPP9 2628/4885 |
| US-20140275018-A1 | NITROGEN CONTAINING COMPOUNDS | NOS2, NOS1, NCF1 | DPP4 3717/4885DPP8 3804/4885DPP9 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.